NASDAQ · Biotechnology

MAZE (MAZE) Stock

$27.88 -2.82% NASDAQ: MAZE Healthcare

Valuation

MetricValue
Price$27.88
Market Cap$1.54B
P/E Ratio-8.11
P/B Ratio3.86
P/S Ratio67.80
EPS (TTM)$-3.05
52-Week High$53.65
52-Week Low$9.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-36.90%
ROA-33.00%
ROCE-40.28%
Gross Margin92.04%
Operating Margin-6.70%
Net Margin-6.13%
Debt/Equity0.18
Current Ratio15.22

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$168.0M$0
Operating Profit$-111.0M$-99.0M$58.0M$-143.0M
Net Profit$-115.0M$-100.0M$52.0M$-131.0M
EPS$-2.63$-2.29$0.08$-3.05
Op Margin——34.4%—

Balance Sheet (USD)

Metric2022202320242025
Total Assets$150.0M$72.0M$241.0M$397.0M
Total Liabilities$49.0M$61.0M$44.0M$42.0M
Cash$100.0M$29.0M$197.0M$189.0M
Borrowings$32.0M$50.0M$27.0M$23.0M

Latest News

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? Motley Fool · Jun 29, 2026 Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk Simply Wall St. · Jun 13, 2026 Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now Insider Monkey · Jun 8, 2026 Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? Motley Fool · Jun 5, 2026 Maze Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire · May 27, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-99.0M$-87.0M$76.0M$-112.0M
Investing Cash Flow$-5.0M$-1.0M$-2.0M$-172.0M
Financing Cash Flow$0$0$0$0
Net Cash Flow$-101.0M$-71.0M$168.0M$-8.0M
Free Cash Flow$-101.0M$-87.0M$75.0M$-113.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-9.01%
Quick Ratio17.88
Interest Coverage—
Return 1Y56.97%
Return 3Y—
Return 5Y—

Ownership

Insiders Held1.46%
Institutions Held95.12%
Institutions Float Held96.54%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 4,567,2742026-03-31
TRV GP IV, LLC4,473,9582026-03-31
Arch Venture Management, Llc4,120,0532026-03-31
Deep Track Capital, Lp3,477,5622026-03-31
Janus Henderson Group PLC2,858,8762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARDX $5.09 +0.49% 11.04 $1.26B 0.00%
BCRXBioCryst Pharmaceuticals, Inc. $9.75 +4.39% -5.40 $2.48B 0.00%
IMNM $23.22 +2.83% -8.13 $2.22B 0.00%
NTLA $10.89 +2.06% -3.55 $1.22B 0.00%
PHVS $32.62 -3.05% -9.75 $2.28B 0.00%

About MAZE

MAZE is led by CEO Jason V. Coloma, publicly traded since 2025.

MAZE stock trades at $27.88 with a market capitalization of $1.54B. The stock is valued at a price-to-earnings (P/E) ratio of -8.11, price-to-book of 3.86, price-to-sales of 67.80. Over the past 52 weeks the stock has ranged between $9.83 and $53.65, and currently trades 48.0% below its 52-week high.

On profitability, MAZE generates a return on equity (ROE) of -36.90%, return on capital employed of -40.28%, an operating margin of -6.70%, a net profit margin of -6.13%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides